Suppr超能文献

成人T细胞白血病-淋巴瘤患者的主要预后因素:一项合作研究。淋巴瘤研究组(1984 - 1987年)

Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987).

出版信息

Leuk Res. 1991;15(2-3):81-90. doi: 10.1016/0145-2126(91)90087-a.

Abstract

A total of 854 patients with anti-HTLV-I antibody positive ATL, newly diagnosed from 1983 to 1987, were analyzed for prognostic factors. There were 466 males and 388 females with a mean age of 57.1. Of these 269 (31.5%) were alive with a median follow-up time of 14 months from diagnosis, while 585 (65.5%) were dead with a median survival time (MST) of 6 months. MST, and projected 2- and 4-year survival rates of all patients were 10 months, 28% and 12%, respectively. A Cox proportional hazards model analysis revealed that five factors, advanced performance status, high lactic dehydrogenase value, age of 40 years or more, increased number of total involved lesions and hypercalcemia, were associated with shortened survival at P less than 0.01. These factors were used to construct a model to identify patients at three different risks for shortened survival. A group of 178 patients (21.8%) with a hazard ratio of less than 0.5 were classified into the low risk (LR) group, 492 (60.4%) with hazard ratio of less than or equal to 0.5 and less than 2.5 into standard high risk (SHR) group, and 145 (17.8%) with hazard ratio of 2.5 or more extremely high risk (EHR) group. MST, and projected 2- and 4-year survival rates were 37 months, 66.3% and 41.2% for LR, 8 months 20.6%, and 4.5% for SHR, and 2.4 months, 5.6% and 0% for EHR, respectively. The risk grouping is of interest in determining the therapeutic strategy of ATL at diagnosis.

摘要

对1983年至1987年新诊断的854例抗人嗜T淋巴细胞病毒I型(HTLV-I)抗体阳性的成人T细胞白血病/淋巴瘤(ATL)患者进行了预后因素分析。其中男性466例,女性388例,平均年龄57.1岁。这些患者中,269例(31.5%)存活,自诊断起的中位随访时间为14个月,而585例(65.5%)死亡,中位生存时间(MST)为6个月。所有患者的MST以及预计的2年和4年生存率分别为10个月、28%和12%。Cox比例风险模型分析显示,五个因素,即晚期体能状态、高乳酸脱氢酶值、40岁及以上年龄、总受累病灶数量增加和高钙血症,与生存期缩短相关,P值小于0.01。这些因素被用于构建一个模型,以识别生存期缩短风险不同的三类患者。178例(21.8%)风险比小于0.5的患者被归为低风险(LR)组,492例(60.4%)风险比小于或等于0.5且小于2.5的患者被归为标准高风险(SHR)组,145例(17.8%)风险比为2.5或更高的患者被归为极高风险(EHR)组。LR组的MST以及预计的2年和4年生存率分别为37个月、66.3%和41.2%,SHR组分别为8个月、20.6%和4.5%,EHR组分别为2.4个月、5.6%和0%。这种风险分组对于确定诊断时ATL的治疗策略具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验